Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,468 across all filing types
Latest filing 2026-01-26 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIRST PARTICIPANTS DOSED IN A 13-WEEK U.S. PHASE II STUDY WITH ASC30, AN ORAL SMALL MOLECULE GLP-1R AGONIST FOR THE TREATMENT OF DIABETES
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by Ascletis Pharma Inc. regarding the commencement of a Phase II clinical trial for their drug candidate ASC30. It provides details on the study design, expected timelines, and previous trial results. It does not constitute a formal financial report, audit, or proxy statement, but rather a business development update. Under the provided filing definitions, such corporate announcements that do not fit into specific categories like M&A or share issues are best classified as Regulatory Filings (RNS).
2026-01-26 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS SELECTS A NEXT-GENERATION ONCE-MONTHLY SUBCUTANEOUSLY ADMINISTERED GLP-1R/GIPR/GCGR TRIPLE PEPTIDE AGONIST, ASC37, FOR CLINICAL DEVELOPMENT
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from Ascletis Pharma Inc. regarding the selection of a new drug candidate (ASC37) for clinical development. It details the drug's properties, potential for future clinical trials, and the company's R&D strategy. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate announcement regarding business development and R&D progress, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate announcements.
2026-01-20 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 December 2025
Regulatory Filings Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Exchanges and Clearing Limited. This is a standard regulatory filing required by the HKEX to report movements in securities, share capital, and treasury shares on a monthly basis. It does not fit into specific categories like 10-K, ER, or IP, and is not a simple announcement of a report (RPA). Therefore, it is classified as a Regulatory Filing (RNS).
2026-01-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, including share capital, treasury shares, and share options. Since it details the company's share repurchase activities and changes in issued shares, it falls under the category of 'Transaction in Own Shares' (POS) as it specifically reports the company buying back its own shares.
2026-01-05 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES U.S. FDA IND CLEARANCE FOR 13-WEEK PHASE II STUDY OF ITS ORAL SMALL MOLECULE GLP-1, ASC30, IN PARTICIPANTS WITH DIABETES
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement from Ascletis Pharma Inc. regarding the U.S. FDA's clearance of an Investigational New Drug (IND) application for a Phase II clinical trial of their drug candidate, ASC30. It details the study design, clinical objectives, and provides context on previous trial results. As this is a regulatory announcement regarding business and clinical development that does not fit into specific financial reporting or corporate governance categories, it is classified as a general regulatory filing.
2026-01-05 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 1% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It details specific share repurchase activities by Ascletis Pharma Inc. on a daily basis. According to the filing definitions, reports of a company buying back its own shares are classified as 'Transaction in Own Shares' (POS).
2025-12-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.